Human leukocyte antigen class I and II molecules presenting measles, mumps, rubella, and varicella-zoster virus peptides (HLA-MMRV peptide complexes)

Human leukocyte antigen (HLA) class I and II molecules are essential glycoproteins that present peptide fragments to the immune system. In the context of MMRV, these molecules present epitopes derived from measles, mumps, rubella, and varicella-zoster viruses. HLA class I molecules present endogenous viral peptides to CD8+ T cells, while HLA class II molecules present exogenous peptides to CD4+ T cells. This presentation is the critical step for activating adaptive immunity and establishing long-term protection against these pathogens. Vaccines like MMR and MMRV utilize live-attenuated viruses to generate these HLA-peptide complexes in the host. The diversity of HLA alleles in the population means that different individuals may present different sets of viral epitopes, affecting vaccine efficacy. These complexes are the primary targets for T-cell receptors, which recognize the specific combination of the HLA molecule and the viral peptide. Monitoring the immune response to these targets often involves measuring antibody titers or T-cell activity. Understanding the interaction between HLA and MMRV peptides is vital for developing next-generation vaccines and managing viral outbreaks (Source: Janeway's Immunobiology, 2017; CDC, 2021).

Other names

MHC-MMRV complexesHLA-restricted viral antigensMajor histocompatibility complex presenting MMRV epitopesHLA-peptide complexes (Measles, Mumps, Rubella, VZV)

The mechanism involves the processing of live-attenuated viral proteins into peptides by antigen-presenting cells, which are then loaded onto HLA class I and II molecules for presentation to T-cell receptors (TCRs), triggering adaptive immune responses (Source: NIH, 2022).